Supporting this notion, the combined treatment of tubastatin with simultaneous knockdown of KYNU and HDAC6 markedly attenuated the expression of C3, C3AR1, and C5AR1, and further reduced GBM cell viability (Figure 5; Supplementary Figure S7). This evidence concerns the gene C3AR1 and glioblastoma.